Release Summary

Trevi Therapeutics’ Phase 2/3 clinical trial of Nalbuphine HCI ER tablets to be presented at the American Academy of Dermatology’s 74th Annual Meeting in Washington, DC on March 5.

Trevi Therapeutics, Inc.